A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder.

Trial Profile

A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 01 Sep 2015 Results of meta analysis of pooled data from 9 trials presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
    • 24 May 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
    • 24 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top